Premium
Mannan‐binding lectin (MBL)‐associated plasma protein present in human urine inhibits calcium oxalate crystal growth
Author(s) -
Kang Insug,
Kim Jin-Il,
Chang Sung-Goo,
Lee Sun-Ju,
Choi Sang-Lim,
Ha Joohun,
Kim Sung Soo
Publication year - 1999
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)01509-4
Subject(s) - calcium oxalate , mannan , chemistry , lectin , calcium , mannan binding lectin , urine , serine protease , biochemistry , recombinant dna , complement system , glycoprotein , in vitro , protease , enzyme , antibody , biology , immunology , polysaccharide , organic chemistry , gene
Mannan‐binding lectin (MBL)‐associated plasma protein (MAp19) is an alternatively spliced form of MBL‐associated serine protease‐2, a component of a complement activation cascade. We observed that MAp19 is excreted in human urine. Interestingly, the amount of MAp19 was higher in urine of renal cell carcinoma patients than healthy people. Pretreatment of urine dialysate with 50 mM EDTA increased the recovery of MAp19, suggesting that MAp19 is a calcium‐binding protein. The recombinant MAp19 showed a strong inhibition of calcium oxalate crystal growth in vitro in a concentration‐dependent manner. Thus, we conclude that MAp19 plays a role in the inhibition of calcium oxalate renal stone formation.